Divestiture • Healthcare Services

Lindora Acquires Zerona Z6

On October 3, 2019, Lindora acquired healthcare services company Zerona Z6 from Erchonia

Acquisition Context
  • This is Lindora’s 1st transaction in the Healthcare Services sector.
  • This is Lindora’s 1st transaction in the United States.
  • This is Lindora’s 1st transaction in Florida.

Explore All 595 Divestiture Healthcare Services Deals - Search the Database Free


M&A Deal Summary

Date October 3, 2019
Target Zerona Z6
Sector Healthcare Services
Buyer(s) Lindora
Sellers(s) Erchonia
Deal Type Divestiture

Target Company

Zerona Z6

Melbourne, Florida, United States
Zerona Z6 is a full body fat loss treatment that allows clients to target areas of stubborn fat and is the first laser specifically designed for body contouring. The technology is FDA Market-Cleared, non-invasive and clinically tested. Zerona Z6 provides an alternative fat loss treatment without the adverse side effects associated with surgical and other weight loss procedures like liposuction and body wraps.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Lindora

Irvine, California, United States

Category Company
Founded 1971
Sector Consumer Services
DESCRIPTION

Lindora is a provider of comprehensive, medically-based weight loss treatments and products. Lindora operates 35 stand-alone clinics across Southern California and seven in-store clinics in selected Rite Aid stores. Lindora was founded in 1971 and is based in Irvine, California.


Deal Context for Buyer #
Overall 1 of 1
Sector: Healthcare Services 1 of 1
Type: Divestiture 1 of 1
State: Florida 1 of 1
Country: United States 1 of 1
Year: 2019 1 of 1

Seller Profile 1

SELLER

Erchonia

Melbourne, Florida, United States

Category Company
Founded 1996
Sector Healthcare Services
DESCRIPTION

Erchonia Corp. is the only company with low-level lasers that were market cleared by the FDA for use with low back pain, onychomycosis, plantar fasciitis, and many other issues. Erchonia has remained committed to furthering the advancement of low-level laser therapy (LLLT) through scientific and clinical studies and the development of FDA Market Cleared lasers.


Deal Context for Seller #
Overall 1 of 1
Sector: Healthcare Services 1 of 1
Type: Divestiture 1 of 1
State: Florida 1 of 1
Country: United States 1 of 1
Year: 2019 1 of 1